FDA Approved: ZARXIO — Supplemental Application (Sandoz Inc.)

View source ↗

Summary

FDA approved a supplemental application for Zarxio (filgrastim-sndz) submitted by Sandoz Inc. Zarxio is a biosimilar to filgrastim used to manage neutropenia re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer Chemotherapy-induced Neutropenia
• Neutropenia

Drugs mentioned

• ZARXIO (FILGRASTIM-SNDZ)

Snippet

SUPPL AP for ZARXIO (FILGRASTIM-SNDZ)